The second‐generation XPO1 inhibitor KPT‐8602 (Eltanexor) has similar mechanism of action and potency as KPT‐330,13 but has greater tolerability than KPT‐330 due to its lower central nervous system penetration14 and exhibits promising antileukaemic activity against AML.15 This evidence concerns the gene XPO1 and acute myeloid leukemia.